Navigation Links
U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter
Date:3/18/2010

picoplatin as a product in development. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties concerning the Company's ability to obtain, maintain and enforce its patents and patent rights and its ability to avoid infringing proprietary rights of others, the risk that the USPTO may not issue patents from the patent applications owned by or licensed to the Company, the risk that the patents may not give the Company advantage over competitors with similar technologies, the potential costs and uncertain outcome of litigation to uphold the validity or enforceability of patents and to prevent infringement; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to enter into strategic partnerships on favorable terms, or at all; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
3. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
4. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Vesselon, Inc. today announced the appointment of Jurgen Raths, ... 2014. Dr. Raths, appointment follows Vesselon,s engagement with Spencer ... a private preferred Series A round to facilitate development ... "Jurgen,s deep experience across multiple functional areas of medical ... as we develop our device that can be compared ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/23/2014)... understanding of how living things function comes from knowledge ... of life, the receptors that are docking stations for ... and RNA that carry genetic blueprints for building cellular ... access to these structural details, a new grant just ... the U.S. Department of Energy (DOE) will fund the ...
(Date:9/23/2014)... New York, N.Y. (PRWEB) September 23, 2014 ... supplement to join the Royal Sport LTD family of ... 100 calories and 20g of pure Whey protein without ... , This ‘Ultra Clean’ protein is available on shelves ... Royal Sport LTD website—where the brand is offering a ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ADOMANI, Inc. ... serving as President and CEO. He is a 13-year veteran ... former President and CEO of A-Z Bus Sales of Colton, ... of their success, growing their top line revenues, profit and ... their gas or diesel to all-electric or plug-in hybrid ...
(Date:9/23/2014)... 2014 Airbus Helicopters Inc. (AHI) is ... as the 2014 Vision Zero Aviation Safety Award ... database, a free flight safety service the company provides ... - Air Medical Specialist for Airbus Helicopters Inc., presented ... check during the Air Medical Transport Conference Annual Community ...
(Date:9/23/2014)... special issue of the European Journal of Cancer ... research presented during the 1st EORTC Cancer Survivorship Summit ... diagnosis, targeted therapeutics, and more personalized multimodal treatments has ... to a large and rapidly increasing number of cancer ... confronted with a broad spectrum of late adverse treatment ...
Breaking Medicine News(10 mins):Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4
... a significantly enhanced quality of life in old age ... less afraid of death than their less religious peers ... professor of sociology at the University of New Hampshire. ... her collaborator, Paul Wink, professor of psychology at Wellesley ...
... for chronic obstructive pulmonary disease (COPD), can be ... new study. The research, presented at CHEST 2006 ... of the American College of Chest Physicians (ACCP), ... a large proportion of subjects with significant impairment. ...
... years will soon be assessed by a new random-dot stereotest ... article published in the November 2006 // issue of Investigative ... children, 38 with various visual impairments and 18 with normal ... alone with their heads stabilized by a chin and front ...
... law which makes possession of child pornography material a federal ... is a pedophile or become one based on the child ... number of cases are going to court and attorneys are ... person has child porn on their computer," said Dr. Humberto ...
... diabetes in middle age could face more complications later in ... new study.// ,Elizabeth Selvin of the Johns Hopkins Bloomberg ... than 2,800 people aged 65 and above with diabetes who ... the online edition of health Magazine WebMD. ,The ...
... Researchers from the Autonomous University of Tamaulipas are putting teeth ... of pacifiers by babies in their first year of birth, ... alignment in complete disarray. ,Researchers are armed to ... children between the ages of 4 and 5 who were ...
Cached Medicine News:Health News:Religious Adults Have a Higher Quality of Life than Their Peers 2Health News:Large Community Spirometry Screening Proves Successful 2Health News:Does Child pornography lead to Child abuse? 2Health News:Does Child pornography lead to Child abuse? 3
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
... 15 mm ISO termination for easy ventilator ... in place., ,D.I.C.® tubes are available ... fenestrated styles. A color-coded system allows quick ... inner cannula. , ,The Portex® line ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Tube, tracheostomy, cuffed, size 8.0, SS, spiral reinforced PVC....
Medicine Products: